Department of Food Science and Human Nutrition, Obesity Research Center, Chonbuk National University, Jeonju, Republic of Korea; Department of Clinical Trial Center for Functional Foods, Chonbuk National University Hospital, Jeonju, Republic of Korea.
Obesity (Silver Spring). 2014 Jan;22(1):63-71. doi: 10.1002/oby.20539. Epub 2013 Sep 5.
The effects of actiponin was investigated, a heat-processed Gynostemma pentaphyllum extract, on body weight, fat loss, and metabolic markers of Korean participants in a 12-week, randomized, double-blind, placebo-controlled clinical trial.
Obese participants (BMI ≥ 25 kg m(-2) and WHR ≥ 0.90 for male or WHR ≥ 0.85 for female) who had not been diagnosed with any disease and met the inclusion criteria were recruited for this study. The 80 subjects were randomly divided into actiponin (n = 40, 450 mg day(-1) ) and placebo (n = 40) groups. Outcomes included measurement of efficacy (abdominal fat distribution, anthropometric parameters, and blood lipid profiles) and safety (adverse events, laboratory test results, electrocardiogram data, and vital signs).
During 12-week of actiponin supplementation, total abdominal fat area, body weight, body fat mass, percent body fat, and BMI were significantly decreased (P = 0.044, P < 0.05, P < 0.0001, P < 0.0001, and P < 0.05, respectively) in the actiponin group compared to the placebo group. No clinically significant changes in any safety parameter were observed.
Our study revealed that actiponin is a potent antiobesity reagent that does not produce any significant adverse effects. These results suggest that actiponin supplementation may be effective for treating obese individuals.
研究一种经过热处理的绞股蓝提取物——actiponin，对韩国参与者体重、脂肪减少和代谢标志物的影响，进行了为期 12 周的随机、双盲、安慰剂对照临床试验。
招募了未被诊断患有任何疾病且符合纳入标准的肥胖参与者（BMI≥25 kg/m²，男性 WHR≥0.90 或女性 WHR≥0.85）。80 名受试者被随机分为 actiponin（n=40，450mg/天）和安慰剂（n=40）组。结果包括测量疗效（腹部脂肪分布、人体测量参数和血脂谱）和安全性（不良事件、实验室检测结果、心电图数据和生命体征）。
在 12 周的 actiponin 补充期间，与安慰剂组相比，actiponin 组的总腹部脂肪面积、体重、体脂肪量、体脂百分比和 BMI 显著降低（P=0.044，P<0.05，P<0.0001，P<0.0001，P<0.05）。未观察到任何安全性参数的临床显著变化。
我们的研究表明，actiponin 是一种有效的抗肥胖试剂，不会产生任何显著的不良反应。这些结果表明，actiponin 补充剂可能对治疗肥胖个体有效。
